Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPantheon Resources plc Share News (PANR)

Share Price Information for Pantheon Resources plc (PANR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.15
Bid: 30.10
Ask: 30.25
Change: 0.00 (0.00%)
Spread: 0.15 (0.498%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 30.15
PANR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

Tue, 29th Aug 2023 10:23

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Pantheon Resources PLC, up 13% at 15.31p, 12-month range 10.10p-136.00p. The oil and gas company focused on onshore operations in the US receives independent expert report. It says the report provides an estimate of contingent resources recoverable from its 100% working interest Kodiak project, formerly known as Theta West. The company adds that the report confirms best estimate contingent resource estimates totalling 962 million barrels for Kodiak Field. Chief Executive Officer Jay Cheatham says: "This really is a big deal. A credible third-party estimate of nearly one billion barrels of recoverable liquids for a company the size of Pantheon is an incredible achievement, validating our geological model."

----------

Faron Pharmaceuticals Ltd, up 11% at 299.80p, 12-month range 155.00p-395.00p. The clinical-stage biopharmaceutical company says that the US Food & Drug Administration has granted orphan drug designation to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. Orphan drug designation gives intellectual property cover and data protection to investigational drugs, as well as potential tax credits on eventual US sales of an approved orphan drug. Bexmarilimab is an immunotherapy designed to overcome resistance to existing treatments for acute myeloid leukaemia, a type of cancer, and myelodysplastic syndromes. "Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to develop bexmarilimab as a potential treatment for AML," says Chief Medical Officer Marie-Louise Fjallskog. Also reports no revenue in the first half of 2023, unchanged year-on-year. Pretax loss widens to EUR13.7 million from EUR13.1 million.

----------

AIM - LOSERS

----------

Pelatro PLC, down 73% at 0.80p, 12-month range 0.69p-24.50p. The marketing software provider decides to cancel shares from AIM market in London, citing costs, management time required, and regulatory burden of maintaining a listing. It will announce schedule for the cancellation, including date of general meeting for shareholders to vote on the plan, "in due course". It will put in place a matched bargain facility to help shareholders buy and sell shares after the delisting. Nic Hellyer resigns as chief financial officer. Leaves board immediately but will remain with company to help with the share cancellation and financial reports. Pelatro says Bangalore-based finance function remains unaffected.

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Sep 2020 15:35

CORRECT: Pantheon Reports "Extraordinary" Talitha Resource Estimate

CORRECT: Pantheon Reports "Extraordinary" Talitha Resource Estimate

Read more
25 Sep 2020 10:39

Pantheon Reports "Extraordinary" Resource Estimate For Talitha

Pantheon Reports "Extraordinary" Resource Estimate For Talitha

Read more
7 Sep 2020 17:29

IN BRIEF: Pantheon Resources Gets Regulatory Boost At Talitha, Alaska

IN BRIEF: Pantheon Resources Gets Regulatory Boost At Talitha, Alaska

Read more
1 Sep 2020 18:05

UK TRADING UPDATE SUMMARY: Gear4music Confident In Annual Outlook

UK TRADING UPDATE SUMMARY: Gear4music Confident In Annual Outlook

Read more
21 Apr 2020 16:00

Pantheon cuts salaries as it continues to seek Alaska farm-out partner

(Sharecast News) - East Texas and Alaska Slope-focussed oil and gas exploration company Pantheon Resources updated the market on Tuesday, saying that in response to recent global events that had negatively affected its sector's outlook, it was reviewing its entire business to reduce non-essential costs.

Read more
21 Apr 2020 13:41

UK TRADING UPDATE SUMMARY: Michelmersh And Titon To Restart Production

UK TRADING UPDATE SUMMARY: Michelmersh And Titon To Restart Production

Read more
26 Mar 2020 12:07

Pantheon Resources Talks Up "World-Class" Portfolio After New Analysis

Pantheon Resources Talks Up "World-Class" Portfolio After New Analysis

Read more
20 Mar 2020 12:08

Pantheon Resources Loss Widens; Backs Oil Prices To Recover

Pantheon Resources Loss Widens; Backs Oil Prices To Recover

Read more
25 Feb 2020 14:44

Pantheon Resources Swings To Profit On Great Bear Bargain Purchase

Pantheon Resources Swings To Profit On Great Bear Bargain Purchase

Read more
31 Jan 2020 17:08

CORRECT: Pantheon Resources Lines Up New Alaska Projects After Review

CORRECT: Pantheon Resources Lines Up New Alaska Projects After Review

Read more
31 Jan 2020 11:35

Pantheon Resources Lines Up Two New Alaska Projects After Review

Pantheon Resources Lines Up Two New Alaska Projects After Review

Read more
2 Jan 2020 09:36

Company Shares Cancelled Or Suspended In London Over Delayed Results

Company Shares Cancelled Or Suspended In London Over Delayed Results

Read more
12 Dec 2019 13:00

Pantheon Resources Secures Additional Oil Leases In Alaska

Pantheon Resources Secures Additional Oil Leases In Alaska

Read more
6 Nov 2019 10:41

Pantheon Resources Continues With Search For Alaska Partner

Pantheon Resources Continues With Search For Alaska Partner

Read more
17 Oct 2019 10:42

Pantheon Resources Buys Outstanding Stake In Alaskan Licences

Pantheon Resources Buys Outstanding Stake In Alaskan Licences

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.